-
Mashup Score: 7Healio Disruptive Innovators Awards Reception - 17 hour(s) ago
2233 S Martin Luther King Dr Chicago, IL 60616 Join Healio | HemOnc Today as we celebrate the risk-takers and groundbreakers at this prestigious awards ceremony. The Disr uptive Innovators awards will span across nine unique categories. Each of the awardees is pioneering the future of hematology/oncology and pushing the status quo toward the betterment of the field. Cocktails and hors d’oeuvres will be
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA approves Breyanzi CAR-T for follicular lymphoma - 3 day(s) ago
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy. Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — often called liso-cel — is a CD19-directed chimeric antigen receptor T-cell therapy.
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Moderate to vigorous aerobic and resistance exercise may improve vascular function among cancer survivors, according to findings presented at American Association for Cancer Research Annual Meeting.In a pilot study, Christina Dieli-Conwright, PhD, MPH, and colleagues from the Dieli-Conwright laboratory at Dana-Farber Cancer Institute randomly assigned 90 sedentary survivors of breast, prostate or
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA’s decision to approve a one-time gene therapy for adults with moderate to severe hemophilia B could have a considerable impact on the treatment landscape, according to a researcher involved in the pivotal trial for the agent.“We certainly hope the impact can be what essentially amounts to a cure,” Adam Cuker, MD, MS, section chief of hematology and associate professor of
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Celebrate a colleague through third annual Healio Honors - 7 day(s) ago
Healio is accepting submissions for its third annual peer-recognition program, Healio Honors. The goal of the program is to celebrate health care professionals who go above and beyond through patient care, advocacy and mentorship.
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Healio Disruptive Innovators Awards Reception - 8 day(s) ago
2233 S Martin Luther King Dr Chicago, IL 60616 Join Healio | HemOnc Today as we celebrate the risk-takers and groundbreakers at this prestigious awards ceremony. The Disr uptive Innovators awards will span across nine unique categories. Each of the awardees is pioneering the future of hematology/oncology and pushing the status quo toward the betterment of the field. Cocktails and hors d’oeuvres will be
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet-
Join us as we announce the winners of the 2024 Disruptive Innovators at our annual awards reception! Hosted by @ShikhaJainMD & @marklewismd, the event will celebrate those pioneering the future of oncology and hematology. RSVP: https://t.co/VReK6JYL89 #HealioInnovators #ASCO24 https://t.co/NIo8ArJSth
-
-
Mashup Score: 1
Online resources about liquid biopsies have several deficits that could prevent patients from learning about the test and better understanding , according to findings published in JAMA Network Open.ideos often lack diversity, can be complex and have lowquality wh web pages have readability scores equivalent to college-level education.
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.CTX130 (CRISPR Therapeutics), an investigational CD70-targeted allogeneic chimeric antigen receptor T-cell therapy, produced promising results in a phase 1 trial for patients with advanced clear-cell renal cell carcinoma (RCC)
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8More than 25% of cancer survivors report mobility disability - 13 day(s) ago
More than one-fourth of cancer survivors reported having a physical disability that diminished their mobility, according to study results published in Journal of Clinical Oncology.Nearly 10% reported a disability that impacted self-care, findings showed.
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Vitamin A before stem cell transplant ‘potentially practice changing’ to lower GVHD risk - 13 day(s) ago
High-dose oral vitamin A prior to hematopoietic stem cell transplantation reduced the incidence of graft-versus-host disease with minimal toxicity, according to study data published in Blood.Results from a randomized phase 2 trial showed improvements in both the incidence of acute graft-versus-host disease (GVHD) and acute gastrointestinal (GI) GVHD 180 days or more after transplant compared with
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
Join us as we announce the winners of the 2024 Disruptive Innovators at our annual awards reception! Hosted by @ShikhaJainMD & @marklewismd, the event will celebrate those pioneering the future of oncology and hematology. RSVP: https://t.co/VReK6JYL89 #HealioInnovators #ASCO24 https://t.co/NIo8ArJSth